Beta-catenin expression is prognostic of improved non-small cell lung cancer survival.

INTRODUCTION The objectives of this study were to determine the frequency and prognostic significance of beta-catenin expression in a cohort of non-small cell lung cancer (NSCLC) patients. METHODS Tissue microarrays were constructed using clinically annotated formalin-fixed paraffin-embedded tumor samples from individuals diagnosed with NSCLC who underwent surgical resection with curative intent and had beta-catenin expression status determined by immunohistochemistry. RESULTS Negative beta-catenin expression was seen in 28% (103/370) of NSCLC cases and was prognostic of a reduced overall patient survival (P = .008) and also was significantly correlated with the presence of lymphatic invasion (P = .015). In multivariate analysis, the loss of beta-catenin expression retained independent prognostic significance and showed an adjusted hazard ratio of 3.18 (confidence interval, 1.46-6.91, P = .004) for reduced patient survival when adjusting for the presence of lymphatic invasion, tumor grade, nodal status, and tumor stage. CONCLUSIONS Beta-catenin represents an important prognostic marker in individuals diagnosed with surgically resectable NSCLC.

[1]  K. Watabe,et al.  Drug development against metastasis-related genes and their pathways: a rationale for cancer therapy. , 2008, Biochimica et biophysica acta.

[2]  J. Retera,et al.  The expression of beta-catenin in non-small-cell lung cancer: a clinicopathological study. , 1998, Journal of clinical pathology.

[3]  W. Jiang,et al.  E‐cadherin and its associated protein catenins, cancer invasion and metastasis , 1996, The British journal of surgery.

[4]  R. Wood‐Baker,et al.  BCL-2 Expression is Prognostic for Improved Survival in Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[5]  L. Liotta,et al.  Tumor invasion and metastasis: an imbalance of positive and negative regulation. , 1991, Cancer research.

[6]  M. Tsao,et al.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation , 2006, Journal of Clinical Pathology.

[7]  G. Brabant,et al.  Wnt/β-Catenin Signaling Mediates Antineoplastic Effects of Imatinib Mesylate (Gleevec) in Anaplastic Thyroid Cancer , 2006 .

[8]  D. Laurents,et al.  The cadherin cytoplasmic domain is unstructured in the absence of beta-catenin. A possible mechanism for regulating cadherin turnover. , 2001, The Journal of biological chemistry.

[9]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[10]  C Blake Gilks,et al.  Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. , 2002, American journal of clinical pathology.

[11]  M. Nishimura,et al.  Increased expression of β‐catenin predicts better prognosis in nonsmall cell lung carcinomas , 2002 .

[12]  K. Sugimachi,et al.  Expression of E-cadherin and β-catenin in human non-small cell lung cancer and the clinical significance , 2000 .

[13]  W. Birchmeier,et al.  Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. , 1994, Biochimica et biophysica acta.

[14]  G. Berx,et al.  Cadherin/catenin complex: A target for antiinvasive therapy? , 1996, Journal of cellular biochemistry.

[15]  Yoshiyuki Niho,et al.  Immunohistochemical α- and β-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma , 2006 .

[16]  F. Hirsch,et al.  The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. , 2002, Lung cancer.

[17]  J. Soria,et al.  Molecular prognostic factors in resectable non-small cell lung cancer. , 2005, Critical reviews in oncology/hematology.

[18]  E. Gabrielson,et al.  High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  K. Kerr,et al.  Expression of CD44v6 but not E‐cadherin or β‐catenin influences prognosis in primary pulmonary adenocarcinoma , 2000, The Journal of pathology.

[20]  M. Pignatelli,et al.  Adhesion molecules: novel molecular tools in tumor pathology. , 1994, Human pathology.

[21]  P. Bunn,et al.  Adjuvant Chemotherapy for Non-Small Cell Lung Cancer , 2007, Cancer investigation.

[22]  Yih-Leong Chang,et al.  The significance of E-cadherin and α-, β-, and γ-catenin expression in surgically treated non–small cell lung cancers of 3 cm or less in size , 2002 .

[23]  B. Molnár,et al.  Immunophenotypic Profiling of Nonsmall Cell Lung Cancer Progression Using the Tissue Microarray Approach , 2007, Applied immunohistochemistry & molecular morphology : AIMM.